Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
DHHS says bill on ibogaine research would clear state path but not permit retail prescribing
Summary
In an executive‑session briefing on House Bill 1772, New Hampshire Department of Health and Human Services chief medical officer Dr. Jonathan Ballard told senators the bill clarifies that researchers may pursue investigational studies of ibogaine but that federal approvals (IRB, NIDA/NIH, DEA) remain required; the state would not license routine prescribing or dispensing.
House Bill 1772 would clarify New Hampshire’s stance on investigational research into ibogaine, a Schedule I substance, but it would not create a pathway for retail prescribing, the state’s public‑health official told the Senate Health and Human Services Committee.
Dr. Jonathan Ballard, chief medical officer at the New Hampshire Department of Health and Human Services, briefed the committee during an executive‑session discussion. Ballard said the amended language makes clear that the state will not add licensing or disciplinary barriers to federally authorized research on Schedule I drugs, but it does not—and cannot—supersede federal controls.
"Ibogaine is a…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
